Listar por agencia financiadora "Market authorization holder of rivaroxaban, Bayer AG"
Mostrando ítems 1-1 de 1
-
Artículo
Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial
(Oxford University Press, 2020)Aims: To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute ...